XML 12 R2.htm IDEA: XBRL DOCUMENT v3.25.0.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Dec. 31, 2024
Sep. 30, 2024
Current Assets:    
Cash and cash equivalents $ 1,100,079 $ 3,251,880
Inventory 14,381,369 8,268,766
Prepaid expenses 2,845,739 2,700,000
Total Current Assets 18,327,187 14,220,646
Operating lease right-of-use asset, net 191,412 246,247
Deposits 38,062 38,062
In-process research and development 92,800,000 92,800,000
Goodwill 9,346,796 9,346,796
Total Other Assets 102,184,858 102,184,858
Total Assets 120,703,457 116,651,751
Current Liabilities:    
Accounts payable 7,364,120 4,927,211
License payable 28,400,000 28,400,000
Accrued expenses 6,242,178 17,027
Accrued compensation 2,595,091 2,229,018
Operating lease liability 204,569 241,547
Total Current Liabilities 44,805,958 35,814,803
Deferred tax liability 6,978,040 6,713,800
Operating lease liability - noncurrent 21,318
Total Liabilities 51,783,998 42,549,921
Commitments and Contingencies
Stockholders’ Equity:    
Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock - $0.001 par value; 16,000,000 shares authorized; 7,727,243 and 7,247,243 shares issued and outstanding at December 31, 2024 and September 30, 2024, respectively 7,727 7,247
Additional paid-in capital 276,538,816 271,440,421
Accumulated deficit (211,138,464) (201,370,218)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity 65,408,079 70,077,450
Non-controlling interest 3,511,380 4,024,380
Total Equity 68,919,459 74,101,830
Total Liabilities and Equity $ 120,703,457 $ 116,651,751